Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused ...
Belite Bio (BLTE) announced that it has entered into a securities purchase agreement with a new, fundamental healthcare investor for the ...
Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs ...
20don MSN
Benchmark analysts have increased the price target for Belite Bio, Inc (NASDAQ:BLTE) shares to $79.00, up from the previous target of $57.00, while reiterating a Buy rating on the stock. The decision ...
仁新(6696)子公司Belite再获国际大型基金1500万美元注资，今日股价跳空开高，一路往上攀升至148.5元，涨幅逼近5%左右。仁新表示，此次增资将充实Belite营运资金，专注LBS-008持续开发，以抢攻全球首款治疗STGD1与GA ...
Belite Bio, Inc (NASDAQ:BLTE) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Belite Bio, Inc, a clinical stage biopharmaceutical ...
JPMorgan Chase & Co. boosted its holdings in shares of Belite Bio, Inc (NASDAQ:BLTE – Free Report) by 7,122.7% in the 3rd ...
分析师修订后的目标价反映了他们预计该药物的平均价格为50,000美元。他们指出，针对罕见遗传性疾病的治疗药物价格可能会显著高于他们的估计。这一更新后的估值并未考虑Tinlarebant在治疗干性年龄相关性黄斑变性（干性AMD）方面的潜力。
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel ...
Belite Bio, Inc. has announced a securities purchase agreement with a new healthcare investor to sell 258,309 American Depositary Shares (ADSs) and warrants at a price of $58.07 per ADS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback